[A comparison analysis of the use of intravenous ß-interferon-1a 30 mcg and subcutaneous ß-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis]. / Sravnitel'nyi analiz rezul'tatov primeneniya v povsednevnoi klinicheskoi praktike dlya lecheniya rasseyannogo skleroza preparatov ß-interferon-1a 30 mkg dlya vnutrimyshechnogo vvedeniya i ß-interferon-1a 44 mkg dlya podkozhnykh in''ektsii.

OBJECTIVE: to compare the results of treatment of multiple sclerosis (MS) with genfaxon, cinnovex and rebif. MATERIAL AND METHODS: The drugs were used in the treatment of 80 patients of the Moscow West administrative okrug during 2014-2015. Thirty patients were treated with genfaxon, 20 with cinnoVex and 30 with the original drug rebif. RESULTS AND CONCLUSION: Twenty-five percent of patients treated with cinnoVex were withdrawn from the study due to the non-efficacy (mean frequency of relapses was the same before and after treatment). A significant decrease of relapses was noted in patients treated with genfaxon. The high frequency of side-effects was the major problem in the treatment withgenfaxon. Due to this reason, some patients stopped treatment.A significant decrease of relapses was noted in patients treated with rebif though aversive effects were frequent during the first year of treatment. The effects of biosimilars found in this study are in line with earlier reports. Therefore, the increase of the quality of interferon-beta-1a biosimilars used for MS treatment is needed.

[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center]. / Opyt primeneniia bioanalogov Β-interferona-1a - sinnoveksa i genfaksona-44 v Moskovskom gorodskom tsentre rasseiannogo skleroza.

OBJECTIVE: To study the efficacy and tolerability of generics (interferon beta-1a biosimilans) cinnovex for intramascular introduction and genfaxon-44 for subcutaneous injections in multiple sclerosis (MS). MATERIAL AND METHODS: One hundred patients were treated with cinnovex and 104 patients were treated with genfaxon-44 during one year. Patient's status was assessed using clinical approach, psychometric scales and MRI. RESULTS AND CONCLUSION: The high percentage of withdrawal of treatment due to the lack of clinical effect and intolerance to the drugs was identified during the treatment. Positive effect with respect to stabilization of MS course was found only in patients who earlier did not receive disease-modifying drugs. Double-blind studies are needed to resolve the question of the adequacy of brand-name drugs and generics.